Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high
New York, January 6, 2026, 09:49 EST — Regular session Alumis Inc (ALMS) shares jumped about 129% in early trade on Tuesday after the drugmaker reported positive late-stage data for its psoriasis pill, envudeucitinib. The stock was at $19.04, up from a previous close of $8.31, after touching $22.30 to set a new 52-week high, Google Finance data showed. Google…